This price target is based on 0 analysts offering 12 month price targets for Origo Acquisition in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
The current consensus among 0 contributing investment analysts is to n/a stock in Origo Acquisition. This N/A consensus rating has held steady for over two years.
Origo Acquisition Corporation, formerly CB Pharma Acquisition Corp., is a shell company. The Company is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company focuses on identifying a business to a particular industry or geographic region of the world. The Company is not engaged in any business operations. As of November 30, 2016, the Company had not generated any revenues.